These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11554259)

  • 21. [Pneumococcal vaccines in children: an update].
    Potin M
    Rev Chilena Infectol; 2014 Aug; 31(4):452-6. PubMed ID: 25327199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence to pneumococcal conjugate vaccination schedule and uptake rate as compared to the established diphtheria-tetanus-acellular pertussis vaccination in Cyprus.
    Hadjipanayis A; Efstathiou E; Michaelidou K; Papaevangelou V
    Vaccine; 2018 Sep; 36(38):5685-5691. PubMed ID: 30115523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An update on the new pneumococcal conjugate vaccine.
    Balter S; Van Beneden C
    Pediatr Ann; 2001 Jun; 30(6):350-3. PubMed ID: 11424855
    [No Abstract]   [Full Text] [Related]  

  • 24. Introduction of pneumococcal conjugate vaccine into the Norwegian childhood vaccination programme.
    Bergsaker MA; Feiring B
    Euro Surveill; 2006 Feb; 11(2):E060202.5. PubMed ID: 16804205
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges.
    Hanquet G; Lernout T; Vergison A; Verhaegen J; Kissling E; Tuerlinckx D; Malfroot A; Swennen B; Sabbe M;
    Vaccine; 2011 Apr; 29(16):2856-64. PubMed ID: 21342667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial.
    Palmu AA; Jokinen J; Nieminen H; Syrjänen R; Ruokokoski E; Puumalainen T; Moreira M; Schuerman L; Borys D; Kilpi TM
    Lancet Respir Med; 2014 Sep; 2(9):717-27. PubMed ID: 25127244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expanded approval for 13-valent pneumococcal conjugate vaccine].
    Pneumologie; 2015 Apr; 69(4):245. PubMed ID: 26038781
    [No Abstract]   [Full Text] [Related]  

  • 29. Parental knowledge, attitudes and perception of pneumococcal disease and pneumococcal conjugate vaccines in Singapore: a questionnaire-based assessment.
    How CH; Phua See Chun P; Shafi F; Jakes RW
    BMC Public Health; 2016 Sep; 16(1):923. PubMed ID: 27590503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of pneumococcal polysaccharide vaccine on nonbacteremic pneumococcal pneumonia.
    Weiser JN; Austrian R
    Clin Infect Dis; 2007 Apr; 44(8):1139-40; author reply 1140-1. PubMed ID: 17366469
    [No Abstract]   [Full Text] [Related]  

  • 31. Letter from the Editor: pneumococcal conjugate vaccine.
    Ellis R
    Hum Vaccin Immunother; 2014; 10(9):2754. PubMed ID: 25483629
    [No Abstract]   [Full Text] [Related]  

  • 32. Vaccine effectiveness of PCV13 in a 3+1 vaccination schedule.
    Weinberger R; van der Linden M; Imöhl M; von Kries R
    Vaccine; 2016 Apr; 34(18):2062-5. PubMed ID: 26920471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pneumococcal vaccination in Europe: schedule adherence.
    Gervaix A; Ansaldi F; Brito-Avô A; Azzari C; Knuf M; Martinón-Torres F; Tuerlinckx D; Tin Htar MT; Syrogiannopoulos GA
    Clin Ther; 2014 May; 36(5):802-12.e1. PubMed ID: 24746990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pneumococcal disease and its prevention. The heptavalent pneumococcal conjugate vaccine].
    de Arístegui Fernández J; Corretger Rauet JM; García Martín F; Hernández-Sampelayo T; Moraga Llop FA; Rodrigo Gonzalo De Liria C; Ruiz Contreras J;
    An Esp Pediatr; 2002 Jan; 56(1):79-90. PubMed ID: 11792258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children.
    Esposito S; Principi N
    J Immunol Res; 2015; 2015():591580. PubMed ID: 26351648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.
    Black S; Shinefield H; Baxter R; Austrian R; Bracken L; Hansen J; Lewis E; Fireman B
    Pediatr Infect Dis J; 2004 Jun; 23(6):485-9. PubMed ID: 15194827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine.
    National Advisory Committee on Immunization
    Can Commun Dis Rep; 2002 Jan; 28(ACS-2):1-32. PubMed ID: 12728645
    [No Abstract]   [Full Text] [Related]  

  • 38. A 10-valent conjugate vaccine for some countries.
    Prescrire Int; 2011 Jan; 20(112):8. PubMed ID: 21462783
    [No Abstract]   [Full Text] [Related]  

  • 39. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia.
    Moore D; Bigham M; Patrick D
    Can Commun Dis Rep; 2003 Jun; 29(11):97-104. PubMed ID: 12794969
    [No Abstract]   [Full Text] [Related]  

  • 40. The prevention of pneumococcal disease by vaccines: promises and challenges.
    Poland GA
    Infect Dis Clin North Am; 2001 Mar; 15(1):97-122. PubMed ID: 11301826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.